Taking into account vitamin D’s immunomodulatory effects, particularly the inhibition of NF-κB by increasing synthesis of IκBα [47,48], we can assume that vitamin D intake and the consequent achievement of a 25(OH)D concentration of 40–50 ng/mL (100–125 nmol/L) might have a positive effect in patients with coronavirus respiratory infections such as Middle East respiratory syndrome, SARS-CoV, and SARS-CoV-2 [11,49]. This evidence concerns the gene NFKBIA and Middle East respiratory syndrome.